A Retrospective Analysis of Clinical Presentation of Lupus Nephritis

Division of Nephrology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas 75390-8856, USA.
The American Journal of the Medical Sciences (Impact Factor: 1.39). 06/2011; 342(6):467-73. DOI: 10.1097/MAJ.0b013e3182199214
Source: PubMed


Lupus nephritis (LN) is an ominous complication of systemic lupus erythematosus, and the risk factors for the disease progression are not well characterized.
In a retrospective study, the authors evaluated the mode of presentation and outcomes of 163 consecutive patients with biopsy-proven LN, who presented to the center between January 1999 and September 2008. Using stepwise logistic regression analysis, the authors assessed risk factors independently associated with response to treatment and to progression to end-stage renal disease (ESRD) in proliferative LN (PLN).
Ninety percent of the patients belonged to minority population. Among 122 patients with class III and IV LN (PLN), 76 patients received intravenous cyclophosphamide and 38 patients received mycophenolate for induction, whereas 34 patients received intravenous cyclophosphamide and 63 patients received mycophenolate for maintenance. Thirty-six (30%) patients with PLN progressed to ESRD, and 3 patients died over a mean follow-up of 37.5 months. In multivariate analysis, chronicity index (CI) (P = 0.0007) and hypertension (P = 0.042) positively correlated with progression to ESRD and death, and CI was associated with increased probability of nonresponse to treatment (P = 0.001). In addition, mycophenolate as maintenance agent was associated with increased likelihood of sustained complete remission and partial remission (P = 0.045).
In patients with LN, hypertension and a high CI are independent risk factors for progression to ESRD or death. Furthermore, a high CI is associated with poor response, and mycophenolate as a maintenance agent may improve the response to treatment.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Lupus nephritis remains one of the most severe manifestations of systemic lupus erythematosus associated with considerable morbidity and mortality. A better understanding of the pathogenesis of lupus nephritis is an important step in identifying more targeted and less toxic therapeutic approaches. Substantial research has helped define the pathogenetic mechanisms of renal manifestations and, in particular, the complex role of type I interferons is increasingly recognized; new insights have been gained into the contribution of immune complexes containing endogenous RNA and DNA in triggering the production of type I interferons by dendritic cells via activation of endosomal toll-like receptors. At the same time, there have been considerable advances in the treatment of lupus nephritis. Corticosteroids have long been the cornerstone of therapy, and the addition of cyclophosphamide has contributed to renal function preservation in patients with severe proliferative glomerulonephritis, though at the cost of serious adverse events. More recently, in an effort to minimize drug toxicity and achieve equal effectiveness, other immunosuppressive agents, including mycophenolate mofetil, have been introduced. Herein, we provide a detailed review of the trials that established the equivalency of these agents in the induction and/or maintenance therapy of lupus nephritis, culminating in the recent publication of new treatment guidelines by the American College of Rheumatology. Although newer biologics have been approved and continue to be a focus of research, they have, for the most part, been relatively disappointing compared to the effectiveness of biologics in other autoimmune diseases. Early diagnosis and treatment are essential for renal preservation.
    No preview · Article · Sep 2012 · Autoimmunity reviews
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Lupus nephritis is the leading cause of chronic kidney disease, and requires renal replacement treatment. There is not much information about its clinicopathological presentation and evolution in the Mexican population. Objective To describe the clinical, histological and treatment characteristics of lupus nephritis patients attended in our institution. Methods This is an observational, longitudinal, and retrospective study. Lupus nephritis patients underwent at least one renal biopsy between January 2004 and January 2012. Results A total of 100 patients were included, of whom 85% were female. The mean onset of lupus nephritis was 13.1×28.1 months, with 63% of patients with a creatinine below 1.3 mg/dL. The most common clinical presentation was nephritic and hematuria-proteinuria syndrome in 68% of cases. Proliferative nephropathy was found in 79% of patients. All patients received the treatment indicated by their nephrologist. A second biopsy was performed on 57% of the patients 12 months after the therapeutic intervention. The findings in the second biopsy led to a modification in immunosuppressive agents in 81% of patients (46/57). Only 10% of the population required dialysis at 12 months. Conclusions Early detection and referral of patients with lupus nephritis allows a treatment that could limit the rapid deterioration of renal function and chronic kidney disease progression.
    No preview · Article · Jun 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Arterial hypertension (HTN) is reported to burden up to 74% of systemic lupus erythematosus (SLE) patients and contributes significantly to accelerated atherosclerosis and increased cardiovascular (CV) risk. Current HTN treatment guidelines have not incorporated lupus patients in their recommendations; whether these guidelines can be fully implemented in SLE is doubtful. A critical appraisal of the existing HTN guidelines in regard to SLE is presented in this review, based upon clinical and experimental data. Particular issues addressed are the time of antihypertensive therapy initiation, the optimal blood pressure level, the antihypertensive agent of first-choice and the need for reduction of the total cardiovascular risk in SLE. Antihypertensive therapy should be recommended at levels of 140/90mmHg (systolic and diastolic BP, respectively) in newly diagnosed lupus patients without overt target organ involvement. In the case of lupus nephritis (LN) or diabetes mellitus (DM), therapy should be implemented at lower levels, such as 130/80mmHg. Hypertensive lupus patients should be considered at high or very high CV risk and, consequently, the optimal BP level should be less than 130/80mmHg. Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) seem to be a safe and efficacious first-choice antihypertensive treatment in lupus patients. Total CV risk should be considered and co-morbidities (dyslipidemia, antiphospholipid syndrome, etc.) should be managed promptly. Current HTN therapeutic guidelines, lacking data from large-scale clinical trials, may not adequately apply to SLE patients. The assessment of the aforementioned recommendations in randomized clinical trials is expected to confirm their value in reducing CV risk in SLE.
    No preview · Article · Aug 2013 · Seminars in arthritis and rheumatism